| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 5% | -50% | $58,352 | +$18,447 | 416,800 | +46% | Armistice Capital, LLC | 30 Jun 2025 |
As of 30 Sep 2025, 1 institutional investors reported holding 7 shares of ZyVersa Therapeutics, Inc. - Common Stock, $0.0001 par value per share (ZVSA). This represents 0% of the company’s total 8,352,705 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 7 | $1 | -$44,731 | $0.14 | 1 |
| 2025 Q2 | 66,068 | $44,732 | -$1,713 | $0.68 | 6 |
| 2025 Q1 | 69,877 | $43,919 | -$27,735 | $0.63 | 7 |
| 2024 Q4 | 81,085 | $86,175 | +$82,931 | $1.06 | 8 |
| 2024 Q3 | 3,009 | $7,220 | -$30,565 | $2.38 | 5 |
| 2024 Q2 | 10,305 | $38,746 | +$38,746 | $3.76 | 4 |